To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06577025
Title A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (aMMbition)
Acronym aMMbition
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | BRA | AUS

Facility Status City State Zip Country Details
City of Hope RECRUITING Duarte California 91010 United States Details
University of California San Francisco RECRUITING San Francisco California 94143 United States Details
University of Iowa Hospital and Clinics RECRUITING Iowa City Iowa 52242 United States Details
Peter MacCallum Cancer Centre RECRUITING Melbourne 3000 Australia Details
The Alfred Hospital RECRUITING Melbourne 3004 Australia Details
Fundacao Antonio Prudente A C Camargo Cancer Center RECRUITING Sao Paulo 01509 900 Brazil Details
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein RECRUITING Sao Paulo 05652 900 Brazil Details
Hosp Clinico Univ de Salamanca RECRUITING Salamanca 37007 Spain Details
Hosp. Univ. Marques de Valdecilla RECRUITING Santander 39008 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field